Analysis for Novartis
Analysis summary
Novartis (NOVN.CH) currently has a total score of 69 points, placing it in the strong range. The score is made up of Performance (55), Stability (84) and Trend (83). The profile is clearly uneven: Stability stands out while Performance is more neutral.
Performance scores 55 points (neutral). Key strength: 1Y return at 30.8 %. Weaker metric: 10Y return at 106.5 %. This points to a sharper upswing more recently.
Stability scores 84 points (very strong). Key strength: current drawdown at 0.0 %. Even the weakest metric remains solid in absolute terms: CAGR/drawdown ratio at 0.23. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 83 points (very strong). Key strength: Price is about 12.8 % above SMA50. Even the weakest metric remains solid in absolute terms: 12M momentum at 18.2 %.
Overall, the profile has a clear strength in Stability, while Performance is the main limiter. On a metric level, current drawdown stands out, while 10Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Novartis fit best in FoxScore?
- Novartis fits a more defensive investor type in FoxScore: stability is the strongest part of the profile. That points to comparatively smaller drawdowns and calmer swings versus the universe — but prices can still fall.
- How meaningful is the available history for Novartis?
- Novartis currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.